149 related articles for article (PubMed ID: 30685184)
1. Severe Protein-Losing Enteropathy Due to an Indolent Splenic Lymphoma: Case Report and Review of the Literature.
Naymagon L; Ward S; Naymagon S; Navada S
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e165-e168. PubMed ID: 30685184
[No Abstract] [Full Text] [Related]
2. MALT lymphoma of the small bowel with protein-losing enteropathy.
Tsukamoto A; Nakamura F; Nannya Y; Kobayashi Y; Shibahara J; Ichikawa M; Fukayama M; Koike K; Kurokawa M
Int J Hematol; 2014 Feb; 99(2):198-201. PubMed ID: 24395281
[TBL] [Abstract][Full Text] [Related]
3. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
4. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
Robinson AC; Nachar VR
J Oncol Pharm Pract; 2020 Jul; 26(5):1248-1253. PubMed ID: 31766968
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis.
Niscola P; Palumbo R; Scaramucci L; Tendas A; Cupelli L; Giovannini M; Piccioni D; Dentamaro T; Perrotti AP; de Fabritiis P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):759-60. PubMed ID: 18500519
[No Abstract] [Full Text] [Related]
6. Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema.
Motosue MS; Howard MT; Butterfield JH
Ann Allergy Asthma Immunol; 2016 May; 116(5):472-3. PubMed ID: 27017557
[No Abstract] [Full Text] [Related]
7. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
8. Membranous glomerulonephritis associated with splenic marginal zone lymphoma mimicking multiple myeloma.
Silva GE; Costa RS; Chahud F; Neto OM; Moyses-Neto M; Romão EA; Dantas M
Clin Nephrol; 2013 Jun; 79(6):488-93. PubMed ID: 23725648
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
10. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
[No Abstract] [Full Text] [Related]
11. Splenic marginal zone lymphoma with increased prolymphocytes.
Cai J; Qing X
Blood; 2021 Jun; 137(22):3150. PubMed ID: 34081119
[No Abstract] [Full Text] [Related]
12. Overlap of lymphatic dysplasia in Fontan-associated protein-losing enteropathy and Mucosa-Associated Lymphoid Tissue (MALT lymphoma): implications for management of protein-losing enteropathy.
Meisner JK; Koblick S; Walling EB; Rabah R; Schumacher KR
Cardiol Young; 2020 Dec; 30(12):1973-1975. PubMed ID: 33012302
[TBL] [Abstract][Full Text] [Related]
13. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone lymphoma leads to sinistral portal hypertension.
Lv XH; Ma LL; Fu WY; Xie Y
J Dig Dis; 2019 Jan; 20(1):45-48. PubMed ID: 30549195
[No Abstract] [Full Text] [Related]
15. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
16. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
Kalpadakis C; Pangalis GA; Sachanas S; Tsirkinidis P; Kontopidou FN; Moschogiannis M; Yiakoumis X; Koulieris E; Dimopoulou MN; Kokkoris SI; Kyrtsonis MC; Siakantaris MP; Tsourouflis G; Korkolopoulou P; Rontogianni D; Tsaftaridis P; Plata E; Papadaki HA; Panagiotidis P; Angelopoulou MK; Vassilakopoulos TP
Blood; 2018 Aug; 132(6):666-670. PubMed ID: 29914978
[No Abstract] [Full Text] [Related]
17. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
18. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
19. Splenic marginal zone B-cell lymphoma associated with primary Sjögren's syndrome.
Nishiyama S; Miyawaki S
Clin Rheumatol; 2004 Jun; 23(3):242-5. PubMed ID: 15168154
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]